Last updated on October 2017

Safety Tolerability and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A


Brief description of study

The trial is conducted in Asia, Europe and North America. The aim of the study is to evaluate the safety of administration under the skin of turoctocog alfa pegol (SC N8-GP) in patients with severe haemophilia A.

Clinical Study Identifier: NCT02994407

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Novo Nordisk

Novo Nordisk Investigational Site
Orlando, FL United States
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
East Lansing, MI United States
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Cleveland, OH United States
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Dayton, OH United States
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Charleston, SC United States
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Milwaukee, WI United States
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Innsbruck, Austria
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Wien, Austria
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Nantes Cedex 1, France
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Berlin, Germany
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Duisburg, Germany
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Homburg, Germany
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Shinjuku-ku, Tokyo, Japan
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Suginami-ku, Tokyo, Japan
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Belgrade, Serbia
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Novi Sad, Serbia
  Connect »